NBI-07-001: Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck (H-23216)
NBI-07-001: A Pilot Study of AuroLase Therapy in Patients with Refractory and/or Recurrent Tumors of the Head and Neck
The purpose of this study is to examine the safety profile of AuroLase Therapy. Treatment includes an intravenous infusion of AuroShell particles and photo-thermal ablation by an interstitial fiber optic probe inserted near and/or inside the tumor. Patients must have measurable disease with one or more unresectable, refractory and/or recurrent tumor of the head and neck. Tumors must be accessible to examination and to biopsy. Tumors must not be within 1 cm of any critical structure to which thermal damage would result in undue risk to the patient. NOTE: Open locally at MEDVAMC only.
For more information:http://www.clinicaltrials.gov/ct2/show/NCT00848042.